Q2 EPS Forecast for CytomX Therapeutics Boosted by Analyst

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – HC Wainwright upped their Q2 2026 EPS estimates for CytomX Therapeutics in a research note issued on Monday, May 11th. HC Wainwright analyst M. Kapoor now forecasts that the biotechnology company will post earnings per share of ($0.09) for the quarter, up from their previous estimate of ($0.13). HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for CytomX Therapeutics’ Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.38) EPS, Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.12) EPS and FY2027 earnings at ($0.47) EPS.

Several other analysts have also weighed in on CTMX. Cantor Fitzgerald raised their price objective on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Guggenheim raised their price target on shares of CytomX Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. JPMorgan Chase & Co. raised shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the company from $7.00 to $12.00 in a report on Monday, March 16th. Piper Sandler raised their price target on shares of CytomX Therapeutics from $10.00 to $12.00 and gave the company an “overweight” rating in a report on Monday, March 23rd. Finally, Weiss Ratings lowered shares of CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, March 19th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.78.

CytomX Therapeutics Trading Up 0.5%

NASDAQ CTMX opened at $3.88 on Wednesday. The firm has a market cap of $660.34 million, a price-to-earnings ratio of -9.46 and a beta of 2.18. The company has a 50 day moving average of $4.56 and a 200-day moving average of $4.54. CytomX Therapeutics has a 1-year low of $1.72 and a 1-year high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.04. The business had revenue of $10.26 million during the quarter, compared to analysts’ expectations of $4.68 million. CytomX Therapeutics had a negative net margin of 166.40% and a negative return on equity of 36.61%.

Institutional Investors Weigh In On CytomX Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN lifted its position in CytomX Therapeutics by 83.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,000 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in CytomX Therapeutics in the 3rd quarter valued at $25,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in CytomX Therapeutics in the 4th quarter valued at $35,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in CytomX Therapeutics in the 3rd quarter valued at $34,000. Finally, May Hill Capital LLC bought a new stake in CytomX Therapeutics in the 4th quarter valued at $46,000. 67.77% of the stock is owned by institutional investors.

Insider Activity

In related news, CFO Christopher Ogden sold 19,323 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total value of $124,053.66. Following the sale, the chief financial officer directly owned 296,948 shares of the company’s stock, valued at approximately $1,906,406.16. The trade was a 6.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Yu-Waye Chu sold 21,279 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $136,611.18. Following the completion of the sale, the insider directly owned 189,446 shares in the company, valued at $1,216,243.32. This represents a 10.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 191,063 shares of company stock valued at $1,226,624. 6.60% of the stock is owned by company insiders.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.